Sign In
Buy GBT
$68.49
+0 (+0%)
At Close: Jan 27, 2023
Should You Buy Global Blood Therapeutics Before This Week's Earnings?
12:55pm, Monday, 04'th May 2020
Global Blood Therapeutics (NASDAQ: GBT) plans to report its first quarter earnings on Wednesday, May 6. Importantly, investors will see the first full quarter of sales for Oxbryta, the company's rece
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
12:00am, Sunday, 03'rd May 2020
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Baxter International (BAX), Biogen (BIIB) and Emergent Biosolutions
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Baxter International (BAX – Research
Gilead Sciences (GILD) Gets a Hold Rating from Morgan Stanley
01:37pm, Friday, 01'st May 2020
In a report released today, Matthew Harrison from Morgan Stanley maintained a Hold rating on Gilead Sciences (GILD), with a price target of $77.00. The
Gilead Sciences (GILD) Gets a Hold Rating from Morgan Stanley
01:37pm, Friday, 01'st May 2020
In a report released today,
Matthew Harrison
from Morgan Stanley maintained a
Hold
rating on Gilead Sciences (
GILD
–
Research Report
), with a price target of
$77.00
. The company’s shares closed
Analysts Offer Insights on Healthcare Companies: Abiomed (ABMD), Amgen (AMGN) and Baxter International (BAX)
01:32pm, Friday, 01'st May 2020
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Abiomed (ABMD), Amgen (AMGN) and Baxter International
Ted W. Love Sells 2,817 Shares of Global Blood Therapeutics Inc (NASDAQ:GBT) Stock
09:04am, Friday, 01'st May 2020
Global Blood Therapeutics Inc (NASDAQ:GBT) insider Ted W. Love sold 2,817 shares of the business’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $80.87, f
Nomura Maintains a Hold Rating on BioMarin Pharmaceutical (BMRN)
02:44pm, Thursday, 30'th Apr 2020
Nomura analyst Christopher Marai maintained a Hold rating on BioMarin Pharmaceutical (BMRN) today and set a price target of $77.00. The company's shares
Nomura Maintains a Hold Rating on BioMarin Pharmaceutical (BMRN)
02:44pm, Thursday, 30'th Apr 2020
Nomura analyst
Christopher Marai
maintained a
Hold
rating on BioMarin Pharmaceutical (
BMRN
–
Research Report
) today and set a price target of
$77.00
. The company’s shares closed last Thursday a
Sarepta Therapeutics (SRPT) Gets a Buy Rating from Nomura
02:39pm, Thursday, 30'th Apr 2020
In a report released yesterday, Christopher Marai from Nomura maintained a Buy rating on Sarepta Therapeutics (SRPT), with a price target of $230.00. The
Nomura Believes Syndax Pharmaceuticals (SNDX) Won't Stop Here
02:37pm, Thursday, 30'th Apr 2020
In a report issued on April 28, Christopher Marai from Nomura maintained a Buy rating on Syndax Pharmaceuticals (SNDX), with a price target of $16.00. The
Nomura Believes Syndax Pharmaceuticals (NASDAQ: SNDX) Won’t Stop Here
02:37pm, Thursday, 30'th Apr 2020
In a report issued on April 28,
Christopher Marai
from Nomura maintained a
Buy
rating on Syndax Pharmaceuticals (
SNDX
–
Research Report
), with a price target of
$16.00
. The company’s shares clo
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Universal Health (UHS), Deciphera Pharmaceuticals (DCPH)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Universal Health (
UHS
–
Research Report
), Deciphera Pharmaceuticals (
DCPH
–
Research Report
) an
